Search Results
Your search for s matches 6860 pages
Showing 101 - 150Unexpected Results in Solid Tumors: What We Learned From Negative Findings
Attendees at the European Society for Medical Oncology (ESMO) Congress 2024 heard the results of many positive clinical trials that will advance the field of cancer treatment. However, a few late-stage trials of promising adjuvant therapies unexpectedly reported negative results. The ASCO Post...
When Cancer and Cardiovascular Disease Intersect
The annual Global Cardio-Oncology Summit (GCOS) was held September 22 to 24 in Minneapolis, with 430 health-care professionals attending from 20 countries. The Summit brings together health-care professionals from diverse disciplines including members of the International Cardio-Oncology...
Eyeing the Future of Oncology: Highlights From the Presidential Symposium at ESMO Congress 2024
At the European Society for Medical Oncology (ESMO) Congress 2024, the Eyes to the Future Presidential Symposium showcased innovative approaches in personalized medicine, immunotherapy resistance, and artificial intelligence (AI)-driven pathology analysis. These presentations, focusing on the...
Evolving Role of MRD Status in Multiple Myeloma
The use of measurable (or minimal) residual disease (MRD) status to guide treatment in multiple myeloma has become a topic of intense interest. Phase III studies presented at the Plenary Session of the 2024 International Myeloma Society Annual Meeting moved MRD status ever closer to validation in...
Sunil S. Badve, MD, FRCPath, on Tumor-Infiltrating Lymphocytes in the Patient With Breast Cancer
Sunil S. Badve, MD, FRCPath, discusses research on tumor-infiltrating lymphocytes in the patient with breast cancer, based in part on his presentation at the Lynn Sage Breast Cancer Symposium, October 2024. Dr. Badve is Professor, Department of Pathology and Laboratory Medicine, and Vice Chair,...
NCCN Harmonized Guidelines for Sub-Saharan Africa: Experts Convene in Ghana to Update Cancer Treatment Guidelines
An international team of oncology experts gathered in Accra, Ghana, for a series of meetings to update cancer treatment recommendations in the National Comprehensive Cancer Network (NCCN) Harmonized Guidelines for Sub-Saharan Africa. Background The NCCN Harmonized Guidelines offer color-coded tiers ...
Use of Aumolertinib Extends Progression-Free Survival in Stage III EGFR-Mutated NSCLC
Aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, has shown efficacy as maintenance therapy for patients with unresectable stage III non–small cell lung cancer (NSCLC) harboring EGFR mutations, according to data presented at the International Association for the Study of Lung Cancer...
Ensuring an Inclusive Environment for Female Minority Oncologists
ASCO’s 2022 State of the Oncology Workforce in America report presented a dismal picture of the representation of Hispanic/Latinx oncologists in the field. According to the report, despite initiatives aimed at increasing diversity in the nearly 13,400 oncology workforce, which includes about 36%...
National Academy of Medicine Elects 100 New Members
The National Academy of Medicine (NAM) announced the election of 90 regular members and 10 international members during its annual meeting. Background Established originally as the Institute of Medicine in 1970 by the National Academy of Sciences, NAM addresses critical issues in health, science,...
I-SPY2.2: Dato-DXd Plus Durvalumab Yields High Pathologic Response Rate in Breast Cancer Subset
In the neoadjuvant I-SPY2.2 trial, a treatment strategy including the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), partnered with the PD-L1 inhibitor durvalumab, yielded a high pathologic complete response rate, especially in immune-positive and “all-negative” subtypes.1...
HypoG-01 Trial: Reducing the Treatment Time for Breast Cancer Nodal Irradiation
A 3-week moderately hypofractionated radiotherapy regimen has been found to be noninferior to the 5-week fractionation when irradiating nodal areas in patients with breast cancer, according to data presented at the European Society for Medical Oncology (ESMO) Congress 2024.1 The 5-year results of...
Conversations on Cancer: Exploring Religious Literacy and Spirituality in Cancer Care
OCE Insights is an occasional department developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, the OCE’s Steven Clark Cunningham, MD, MLA, FACS, Clinical Reviewer on the Gastrointestinal Cancers Team, ...
CARMEN-LC03: Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC
The multicenter phase III CARMEN-LC03 trial did not meet its dual primary endpoints of progression-free and overall survival with the CEACAM5-directed antibody-drug conjugate tusamitamab ravtansine vs standard chemotherapy with docetaxel in previously treated patients with advanced nonsquamous...
Patient-Level Data Support Perioperative Use of Nivolumab in Resectable NSCLC
An examination of patient-level data from the phase III CheckMate 816 and CheckMate 77T trials supports the perioperative use of the PD-1 inhibitor nivolumab plus chemotherapy, as compared with the neoadjuvant use of nivolumab plus chemotherapy without adjuvant therapy, in resectable non–small...
ADRIATIC Trial: Durvalumab Consolidation Extends Survival in Limited-Stage Small Cell Lung Cancer
Consolidation therapy with the PD-1 immune checkpoint inhibitor durvalumab is set to become the new global standard of care for patients with limited-stage small cell lung cancer (SCLC), according to groundbreaking data presented at the European Society for Medical Oncology (ESMO) Congress 2024.1...
Cancer Provider Groups Across the Country Urge Congress to Pass Prior Authorization Reform
The Association for Clinical Oncology (ASCO), along with 46 state oncology societies, sent a letter to U.S. House and Senate leadership urging Congress to pass the Improving Seniors’ Timely Access to Care Act (H.R. 8702/S. 4532), which would streamline prior authorization practices within Medicare...
ASCO Updates Stage III NSCLC Guideline to Include Osimertinib in Wake of LAURA Trial Data
ASCO has issued a rapid update to its guideline on the management of stage III non–small cell lung cancer (NSCLC), based on the results of the phase III LAURA trial, which was presented at the 2024 ASCO Annual Meeting and published simultaneously in The New England Journal of Medicine.1,2 The...
PEACE-3: Enzalutamide Plus Radium-223 Significantly Improves Survival in Metastatic Castration-Resistant Prostate Cancer
Initial analysis from the PEACE-3 trial suggests that the addition of radium-223 dichloride to enzalutamide could offer a promising new first-line treatment option for patients with metastatic castration-resistant prostate cancer, according to data presented by lead study author, Silke Gillessen,...
DESTINY-Breast12: T-DXd of Benefit in Patients With Breast Cancer and Brain Metastases
Late-breaking findings from the phase IIIb/IV, open-label DESTINY-Breast12 trial support the use of the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) in patients with HER2-positive metastatic breast cancer and brain metastases who have experienced disease progression on at least...
‘Encouraging’ Pathologic Responses Achieved With Novel Combination Regimen in Early-Stage NSCLC
In the multiarm phase II NeoCOAST-2 trial, neoadjuvant treatment with datopotamab deruxtecan (Dato-DXd) plus the monoclonal antibody durvalumab and single-agent platinum chemotherapy led to promising rates of pathologic complete and major pathologic responses in patients with early-stage non–small...
Conversations on Cancer: Exploring Religious Literacy and Spirituality in Cancer Care
OCE Insights is an occasional department developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, the OCE’s Steven Clark Cunningham, MD, MLA, FACS, Clinical Reviewer on the Gastrointestinal Cancers Team, ...
Navigating Uncharted Waters in the Post-Chevron Sea Change
It is not often that the oncology community looks to the Supreme Court to forecast its future. In 2024, two decisions seemingly unrelated to health care were issued that are likely to have a monumental impact on oncology care delivery. The Court’s rulings—on June 28, Loper Bright Enterprises et ...
Standard Chemoradiation May Be Superior to Deintensification Approaches in Patients With HPV-Associated Oropharyngeal Cancer
Deintensified treatment involving a lower radiation dose and immunotherapy in place of chemotherapy may not perform as well as a more rigorous chemoradiation treatment approach in patients with early-stage human papillomavirus (HPV)-associated oropharyngeal cancer, according to new findings...
Amivantamab-vmjw Plus Lazertinib Improves Long-Term Outcomes in First-Line Setting of EGFR-Mutant Advanced NSCLC
The combination of the EGFR-MET bispecific antibody amivantamab-vmjw and the EGFR tyrosine kinase inhibitor lazertinib continues to demonstrate superior efficacy compared with the kinase inhibitor osimertinib alone in the first-line treatment of EGFR-mutant advanced non–small cell lung cancer...
Community-Academic Partnership May Successfully Reduce Radon-Related Lung Cancer Risk in Native Population
A community and academic partnership may provide effective education about the risks of radon, testing for radon, mitigating radon in homes with high levels of the chemical, and reducing the risk of developing lung cancer among Native community members residing in Wisconsin, according to new...
A Clinical Trial Has Halted Progression of Merkel Cell Carcinoma and Allowed Me to Pursue My Love of Music
At the age of 75, I’m just happy to still be here and be able to continue to contribute to my musical community. When I was diagnosed with Merkel cell carcinoma in 2021, I had never heard of the cancer and didn’t realize how aggressive and deadly it is. It was especially surprising to get such a...
Combination Targeted Therapy Produces Durable Remissions in Some Patients With Relapsed Diffuse Large B-Cell Lymphoma
The results from a phase Ib/II study of a five-drug targeted therapy regimen—venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR)—in the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) showed the treatment produced durable remissions and potential...
ASCO Issues First Guideline Specific to Locally Advanced Rectal Cancer
ASCO has released its first clinical practice guideline focused specifically on the management of locally advanced rectal cancer.1 “Rectal cancer, and especially locally advanced rectal cancer, is a complex disease that requires individualized approaches using multimodality therapies to have the...
Optimizing the Use of Multicancer Early Detection Tests
Multicancer early detection (MCED) tests are beginning to enter clinical practice, but how useful will they be? “This is an exciting field, with many competing technologies. MCED assays will be coming across your desk in the near future if they haven’t already. But they are not a panacea. They are ...
Use of Immune Checkpoint Inhibitors Under Study in High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer
Clinical trials are now demonstrating the value of immune checkpoint inhibitors as neoadjuvant therapy in certain subsets of patients with hormone receptor–positive, HER2-negative breast cancer. Hope S. Rugo, MD, FASCO, described this newer approach—specifically, which subsets of patients may...
The Formative Years of Medical Oncology in the United States: A Rough and Tumble Road, Part 2
Medical oncology had a turbulent beginning, as we explained in part 1 of this commentary published in the September 25, 2024, issue of The ASCO Post. And although no other specialty we know of struggled as much, with perseverance and time, it had become a stable specialty of internal medicine by...
The Formative Years of Medical Oncology in the United States: A Rough and Tumble Road, Part 1
Medical oncology had a turbulent beginning. No other specialty we know of struggled as much. But by 1980, it had become a stable specialty of internal medicine and was off and running—with the major problem of how to marshal available resources to freely test the myriad opportunities presented by ...
HARMONi-2: Ivonescimab Outperforms Pembrolizumab as First-Line Treatment in NSCLC
In a phase III study conducted in China, the bispecific antibody ivonescimab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with the PD-1 inhibitor pembrolizumab as a first-line treatment of PD-L1–positive advanced non–small...
Too Much, Too Little, Just Right: Optimizing Cancer Care for Older Adults
Imagine walking into a fancy restaurant only to find a menu consisting mostly of kids’ dishes. It would make no sense. Just 25% of restaurant diners are younger than age 12, and they rarely write Yelp reviews. But when it comes to cancer treatment, this is not very far from what we do. The median...
IDEA Awardees’ Reflections on the 2024 ASCO Annual Meeting
It happened! We received the International Development and Education Award (IDEA) from Conquer Cancer®, the ASCO Foundation, and it was a journey of growth, global collaboration, leadership, mentorship, and more. We have much to share after this breakthrough in our careers. The ASCO Annual Meeting...
Phase III ALEXANDRA/IMpassion030: No Survival Benefit for Adjuvant Atezolizumab in Triple-Negative Breast Cancer
In patients with early-stage triple-negative breast cancer, the addition of atezolizumab to standard adjuvant chemotherapy provided no benefit over chemotherapy alone in the final analysis of the phase III ALEXANDRA/IMpassion030 trial. The results were presented at the 2024 European Breast Cancer...
New Collaborative Guideline Highlights the Importance of Multidisciplinary Care for Patients With Osteoradionecrosis
A joint guideline from the International Society of Oral Oncology–Multinational Association for Supportive Care in Cancer and ASCO seeks to fill a gap in the clinical guidance for patients with head and neck cancers who develop osteoradionecrosis following their head and neck radiation therapy.1...
Use of Immune Checkpoint Inhibitors Under Study in High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer
Clinical trials are now demonstrating the value of immune checkpoint inhibitors as neoadjuvant therapy in certain subsets of patients with hormone receptor–positive, HER2-negative breast cancer. Hope S. Rugo, MD, FASCO, described this newer approach—specifically, which subsets of patients may...
T-DXd Effective for Breast Tumors With HER2-Low and HER2-Ultralow Expression in Earlier Line of Therapy
In patients with hormone receptor–positive metastatic breast cancers with HER2-low or HER2-ultralow expression, treatment with the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) was found to be superior to chemotherapy after one or more lines of endocrine therapy. In...
What Is the Better Target for Bispecific Antibodies in Multiple Myeloma: BCMA or GPRC5D?
For relapsed or refractory multiple myeloma, there are three available bispecific antibodies—two that target B-cell maturation antigen (BCMA) and one that targets G protein–coupled receptor class C group 5 member D (GPRC5D). Which is the preferred target? This question was addressed at the 2024...
Remembering a Pioneer in Melanoma and Immunotherapy: Jeffrey S. Weber, MD, PhD, FASCO
Jeffrey S. Weber, MD, PhD, FASCO, an internationally recognized pioneer in melanoma and cancer immunotherapy, died on August 19, 2024, according to an announcement from the Melanoma Research Foundation. He most recently served as Deputy Director of the Laura and Isaac Perlmutter Cancer Center at...
Hypofractionated vs Conventionally Fractionated Radiation After Implant-Based Breast Reconstruction
In a trial reported in JAMA Oncology, Julia S. Wong, MD, and colleagues found that hypofractionated postmastectomy radiation therapy did not improve outcomes in the physical well-being domain of the Functional Assessment of Cancer Therapy–Breast (FACT-B) assessment vs conventionally fractionated...
BTK Degraders and CELMoDs: Novel Mechanisms Overcoming Resistance in Hematologic Malignancies
Despite advances in targeted therapies for hematologic malignancies, drug resistance and persistent side effects continue to challenge clinicians and limit patient outcomes, underscoring the urgent need for novel therapeutic approaches. At the 2024 Pan Pacific Lymphoma Conference, Marc S. Hoffmann, ...
ASCO Guideline Update Highlights the Importance of Early Integration of Palliative Care for Patients With Cancer
Growing awareness of the benefits of palliative care in patients with cancer has prompted ASCO to update its recommendations for clinicians, patients, caregivers, and health-care organizations on integrating palliative care in oncology.1 The updated guideline reinforces prior recommendations in the ...
An Integrated Approach to Treating Cancer and Cardiovascular Disease: When Oncologists and Cardiologists Collaborate
At the 2024 Debates and Didactics in Hematology and Oncology Conference, sponsored by Emory’s Winship Cancer Institute, cardiologist-by-training Anant Mandawat, MD, FACC, briefly reviewed how the emerging field of cardio-oncology is blazing a path toward “bigger and bolder cancer care” and offered...
LIBRETTO-431 Trial Shows Selpercatinib Is Effective in East Asian Patients With RET Fusion–Positive Non–Small Cell Lung Cancer
A subgroup analysis of data from the LIBRETTO-431 trial (ClinicalTrials.gov identifier NCT04194944) showed that the selective RET inhibitor selpercatinib safely improved progression-free survival compared to chemotherapy plus pembrolizumab in East Asian patients diagnosed with RET fusion–positive...
Age Is Just a Number: Treatment Considerations for Endometrial Cancer in Older Women
Endometrial cancer is most frequently diagnosed among women aged 55 to 65, with a median age at diagnosis of 64 years.1 In epidemiologic studies, women diagnosed with endometrial cancer at an older age are more likely to have high-grade disease, aggressive histology, deep myometrial invasion, lower ...
What Is the Optimal First-Line Therapy for Chronic Lymphocytic Leukemia?
Is the optimal first-line treatment of chronic lymphocytic leukemia (CLL) monotherapy with a Bruton’s tyrosine kinase (BTK) inhibitor or some combination regimen? This clinical question was explored by two speakers at the 2024 Pan Pacific Lymphoma Conference, sponsored by the University of...
Discontinuation of CML Therapy: Which Patients Are Ideal Candidates?
With the introduction of tyrosine kinase inhibitors, chronic myeloid leukemia (CML) has become a chronic disease for most patients. Furthermore, we now know that some patients can successfully stop treatment and remain in remission. “Stopping tyrosine kinase inhibitor therapy is something we get a...
Physician Community Comes Together to Urge Congress to Act on Medicare Payment Reform
ASCO, along with more than 100 medical organizations and societies, sent a letter to members of the U.S. House and Senate leadership urging Congress to prioritize and advance several bills and legislative proposals that would provide greater fiscal stability for physicians and reform key elements...
